Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 29 September 2017

Summit Therapeutics plc : Exercise of Share Options

     

Published: 19:20 CEST 29-09-2017 /GlobeNewswire /Source: Summit Therapeutics plc / : SUMM /ISIN: GB00BN40HZ01

Summit Therapeutics plc : Exercise of Share Options

Summit Therapeutics plc

("Summit" or the "Company")

 

EXERCISE OF SHARE OPTIONS

 

Oxford, UK, 29 September 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that, following the exercise of employee share options, the Company has issued 94,425 new ordinary shares of 1p each (the "New Ordinary Shares").

 

Application will be made for the admission to trading on AIM of the New Ordinary Shares, which will rank pari passu with the Company's existing ordinary shares, and admission is expected to occur on or around 6 October 2017. 

 

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will 70,443,833.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

- END -

 

For more information, please contact:

 

Summit Therapeutics
Richard Pye (UK office)

Erik Ostrowski (US office)

 

 

Tel: +44 (0)1235 443 951

       +1 617 294 6607

Cairn Financial Advisers LLP
(Nominated Adviser)

Liam Murray / Tony Rawlinson

 

 

 

Tel: +44 (0)20 7213 0880

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Summit Therapeutics plc, 85b Park Drive Milton Park, Abingdon OX14 4RY,, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.